Cotización Genedrive - GDR

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Último Precio

2.05

Postura de Compra

2.00

Postura de Venta

2.10

Volume Operado de la Acción

14,836,648

1.795 Rango del Día 2.225

1.425 Rango de 52 semanas 11.85

Capitalización de Mercado [m]

11.134M

Precio Anterior

1.83

Precio de Apertura

1.875

Hora

20000

2.084

(O)

Última hora de negociación

Volumen financiero

258,692p

Precio Promedio Ponderado

1.7436

Volumen promedio (3 m)

9,902,827

Acciones en circulación

543,141,481

Rendimiento del Dividendo

Ratio Precio/Utilidad

-2.16

Beneficio por acción (BPA)

-0.01

turnover

55k

Beneficio neto

-5.15M

Sector

Coml Physical, Biologcl Resh

Industria

Coml Physical, Biologcl Resh

Sitio web

www.genedriveplc.com

Sede

Manchester, Gbr

Fundado

Genedrive Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GDR. The last closing price for Genedrive was 1.83p. Over the last year, Genedrive shares have traded in a share price range of 1.425p to 11.85p.

Genedrive currently has 543,141,481 shares in issue. The market capitalisation of Genedrive is £9.94 million. Genedrive has a price to earnings ratio (PE ratio) of -2.16.

Genedrive PLC Block listing returns

Genedrive PLC 29 November 2024 genedrive plc ("genedrive" or the "Company") Block Listing Returns The Company confirms the block listing six monthly return for the period to 29...

Genedrive annual loss widens due to increased expenses

Genedrive PLC on Friday said its loss widened during its most recent financial year, as its expenses ramped up. The ...

Genedrive PLC Final Results

Genedrive PLC 29 November 2024 genedrive plc ("genedrive" or "the Company" or "the Group") Audited Final Results genedrive plc (AIM: GDR), the point of care pharmacogenetic testing...

Genedrive PLC Notice of Results

Genedrive PLC 22 November 2024 genedrive plc ("genedrive" or the "Company") Notice of Results Investor Presentation genedrive plc (AIM: GDR), the point of care pharmacogenetic testing...

Genedrive PLC NIHR and OLS Funding Package

Genedrive PLC 21 November 2024 genedrive plc ("genedrive" or the "Company") NIHR and OLS Funding Package to address NICE Real World Evidence Generation Requirements for the Genedrive®...

*Genedrive featured in UK Department for Business & Trade's genomics spotlight

...

Genedrive PLC Scottish Health Technology Group publications

Genedrive PLC 04 November 2024 genedrive plc ("genedrive" or the "Company") Scottish Health Technology Group publishes two Technology Assessments including genedrive's CYP2C19 ID and...

Genedrive PLC Director Declaration

Genedrive PLC 21 October 2024 genedrive plc ("genedrive" or the "Company") Director Declaration genedrive plc (AIM: GDR), the point of care Pharmacogenetic testing company, announces...

Genedrive PLC Director/PDMR Shareholding

Genedrive PLC 15 August 2024 genedrive plc ("genedrive" or the "Company") Director/PDMR Notification genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, makes...

Genedrive PLC First UK commercial sales of the CYP2C19-ID Kit

Genedrive PLC 12 August 2024 genedrive plc ("genedrive" or the "Company") First UK commercial sales of the Genedrive® CYP2C19-ID Kit genedrive plc (AIM: GDR), the point of care...